ARTISAN BIOPHARMA
Advancing new therapies for pediatric cancers, aiming for cure
Artisan Biopharma –
A for-profit subsidiary of cc-TDI
(LLC and Public Benefit Company)
artisan biopharma
We craft medicines
Our mission is to turn breakthrough science into clinically validated therapies for pediatric
cancers. Founded in 2019, Artisan Biopharma consists of a collaborative team of scientists and enterprise-level professionals approaching the common goal to make childhood cancer universally survivable.
CURING THE UNCURABLE
Our Mission
Few rare patient populations are as vulnerable and in need of advocacy as
children with cancer. Pharmaceutical companies face many disincentives challenges to pursue
pediatric oncolytics, including low incidence,, uniqueness of mechanisms relative to adult indications, and lack of
funding for early-stage research.
Artisan is leveraging the deep preclinical domain expertise of the Children’s Cancer Therapy
Development Institute, cc-TDI, to reverse the drug approvals for pediatric cancer. Our goal is to support advancement of transformational candidates to the clinic for pediatric indications on a routine basis.
The Children’s Cancer Therapy Development Institute (cc-TDI) has since spent more than a
decade devoted to the research of rare, aggressive, and difficult-to-treat pediatric cancers,
supported by NIH, foundation-level grants, and proactive individuals & families.
A new way pediatric oncology drugs are brought to market
24 years in pediatric cancer research
We collaborate with industry and academic Partners.
Inspired Solutions
We redefine medicine
A team of like-minded individuals launched Artisan Biopharma with the aim of using the knowledge and experience of cc—TDI to disrupt the status quo of the pediatric cancer drug development process. Simply said, the Artisan team will curate and accelerate clinical trials to get better treatment options to our children, faster.
ARTISAN BIOPHARMA
Investment Highlights
We address an unmet clinical need for treatment of children with cancer while innovatively addressing the paradox of childhood cancer drug development: while childhood cancers are rare , our childhood cancer bioPROTAC drug in development for rhabdomyosarcoma and an antibody-drug conjugate for diffuse intrinsic pontine glioma (DIPG) haves secondary markets for adult-onset diabetes and adult glioblastoma respectively.
Validated Partners
We collaborate with industry and academic Partners in sarcoma, brain tumors, and other pediatric cancer research, as well as prominent UK Universities.
De-Risked Platform
Leveraging clinically proven mRNA delivery (COVID learnings) and established nanobody screening libraries.